ArticleBreast cancer research and treatment2020
Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- The effects of a financial navigation intervention on financial toxicity among patients with breast cancer in China: A randomized controlled trial.Breast (Edinburgh, Scotland) · 2026Trial
- The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.Breast cancer research and treatment · 2026Article
- The broad societal value of pembrolizumab for women's cancer in Canada.Future oncology (London, England) · 2026Article
- Healthcare costs and resource use in advanced breast cancer at the end of life: a register study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Ensemble machine learning for predicting costs and cost influencers in breast cancer surgery.BMC health services research · 2025Article
- Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9).Breast (Edinburgh, Scotland) · 2025Review
- First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis.Oncology letters · 2024Article
- Catchment area and cancer population health research through a novel population-based statewide database: a scoping review.JNCI cancer spectrum · 2024Article
- Financial burden among metastatic breast cancer patients: a qualitative inquiry of costs, financial assistance, health insurance, and financial coping behaviors.Cancer causes & control : CCC · 2024Article
- Psychosocial and supportive care concerns of young women living with advanced breast cancer: baseline findings from a prospective virtual support intervention study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database.Breast cancer research and treatment · 2024Article
- Prevalence, incidence, and mortality rates of breast cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2019.Frontiers in public health · 2023Article
- Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- The DISCO App: A pilot test of a multi-level intervention to reduce the financial burden of cancer through improved cost communication.PEC innovation · 2022Article
- Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.JAMA network open · 2022Article
- The influence of cross-regional medical treatment on total medical expenses, medical insurance payments, and out-of-pocket expenses of patients with malignant tumors in Chinese low-income areas.Cost effectiveness and resource allocation : C/E · 2022Article
- Article
- Health care costs for adolescents and young adults with cancer: a Wisconsin community-based hospital study between 2005 and 2020.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.JNCI cancer spectrum · 2021Article
- Challenges in Predicting Future Costs for Metastatic Breast Cancer.JNCI cancer spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal.
methodsWe used 2003-2014 North Carolina cancer registry data linked with administrative claims from public and private payers. We developed a claims-based algorithm to identify breast cancer patients who progressed to metastatic disease. We matched breast cancer patients (mBC and earlier stage) to non-cancer patients on age group, county of residence, and insurance plan. Outcomes were average monthly medical expenditures and expected medical expenditures by phase. We used regression to estimate excess costs attributed to mBC as the difference in mean payments between patients with mBC (N = 4806) and patients with each earlier-stage breast cancer (stage 1, stage 2, stage 3, and unknown stage; N = 21,772) and non-cancer controls (N = 109,631) by treatment phase and age group.
resultsAdjusted monthly costs for women with mBC were significantly higher than for women with earlier-stage breast cancer and non-cancer controls for all age groups and treatment phases except the initial treatment among women with stage 3 breast cancer at diagnosis. The largest expected total costs were for women aged 18-44 with mBC during the continuing phase ($209,961 95% Confidence Interval $165,736-254,186).
conclusionsWe found substantial excess costs for mBC among younger women and during the continuing and terminal phases of survivorship. It is important to assess whether this care is high value for these women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.